Clinical trial
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of…
NCT00363311 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00363311 |
|---|---|
| Title | Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Neoplasms, Prostate |
| Intervention type | Drug |
| Interventions | Dutasteride, Matching placebo |
| Enrollment | 302 |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Aug 15, 2006 |
| Last update posted | Jan 18, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: